0.375
0.02 (4.17%)
| Previous Close | 0.360 |
| Open | 0.360 |
| Volume | 33,814 |
| Avg. Volume (3M) | 188,503 |
| Market Cap | 61,320,372 |
| Price / Sales | 41.79 |
| Price / Book | 8.69 |
| 52 Weeks Range | |
| Earnings Date | 28 Jul 2025 - 1 Aug 2025 |
| Profit Margin | -203.39% |
| Operating Margin (TTM) | -548.94% |
| Diluted EPS (TTM) | -0.060 |
| Quarterly Revenue Growth (YOY) | 35.50% |
| Total Debt/Equity (MRQ) | 4.69% |
| Current Ratio (MRQ) | 4.70 |
| Operating Cash Flow (TTM) | -5.46 M |
| Levered Free Cash Flow (TTM) | -2.92 M |
| Return on Assets (TTM) | -66.25% |
| Return on Equity (TTM) | -136.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | PROTEOMICS FPO [PIQ] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 24.03% |
| % Held by Institutions | 5.59% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |